Hepatoprotective effects of silymarin in management of liver injury caused by tuberculosis treatment

Abstract

Tuberculosis (TB) is a chronic infection of global-health concern because of its high incidence, costly medical treatment, drug resistance and risk of co-infections. Anti-TB treatment involves a combination of drugs with high degree of liver toxicity, leading to drug-induced liver injury in 2–28% of patients who receive anti-TB treatment. In this case report, a patient with TB experienced drug-induced liver injury, and the initiation of treatment with silymarin 140 mg three-times daily resulted in a significant hepatoprotective effects as shown by the decreased liver enzyme activity. This article is part of the Current clinical use of silymarin in the treatment of toxic liver diseases: a case series Special Issue: https://www.drugsincontext.com/special_issues/current-clinical-use-of-silymarin-in-the-treatment-of-toxic-liver-diseases-a-case-series

Review and expert opinion on MAFLD, oxidative stress and multifunctional management

“…Various studies have been conducted or are ongoing to further confirm the evidence on silymarin and improve its clinical use. [54][55][56][57][58][59]…”

Chronic liver disease and management with silymarin: an introductory review of a clinical case collection

“…Common triggers for DILI include certain medications such as antituberculosis drugs (anti-TB), antiepileptics and antibiotics. 10 Furthermore, the prolonged and excessive usage of herbal supplements, traditional medicines and dietary supplements has emerged as a significant contributor to HILI. 18,24 Notably, in the collection of clinical cases across the globe presented in this series, [5][6][7][8][9][10] at least one risk factor was found to be present in all the described CLD cases (except for DILI).…”

“…10 Furthermore, the prolonged and excessive usage of herbal supplements, traditional medicines and dietary supplements has emerged as a significant contributor to HILI. 18,24 Notably, in the collection of clinical cases across the globe presented in this series, [5][6][7][8][9][10] at least one risk factor was found to be present in all the described CLD cases (except for DILI). This finding is in alignment with the available literature around NAFLD/MAFLD, where most patients have one or more risk factors, including overweight/obesity, T2D, dyslipidaemia or cardiovascular complications like hypertension.…”

“…This review is an opening paper to the clinical case collection entitled 'Current clinical use of silymarin in the treatment of toxic liver diseases: a case series', focused on the management and treatment of major liver diseases with silymarin. [5][6][7][8][9][10]…”